A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to ...

Ian Everard warns of a looming precious metals supply crunch. He highlights manipulated markets, dwindling silver stocks, and ...

The FDA has granted orphan drug designation to Plus Therapeutics’ injectable radiotherapy, Rhenium (186Re) Obisbemeda.

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

Researchers have developed a drug shown to significantly extend survival time for patients with glioblastoma, the most common primary brain tumor in adults, according to results of a new trial.

ReSPECT- LM Phase 1 single dose is now complete, and the recommended Phase 2 dose (RP2D) for single administration therapy has been determinedAUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus ...

Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung ...

Rhenium and technetium not only share the same group in the periodic table, but also have some common history relating to how they were — or indeed weren't — discovered. Eric Scerri explains.

Plus Therapeutics (PSTV) announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D. The ...

An investigational drug for glioblastoma more than doubled survival and progression-free time compared to standard rates. | ...

A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to extend survival for patients with glioblastoma, the most common primary brain ...

Plus Therapeutics (PSTV) announces the publication of results in a peer-reviewed manuscript titled, “Treatment of Recurrent Glioma by Rhenium ...